Supplementary material

Methodology: Sample

The medication data recorded in the UK Biobank was collected through a verbal interview with a trained nurse. Participants were asked if they were currently taking any regular prescription medication. If they answered yes, the nurse asked them to detail medication they were taking. Dose, formulation or duration of treatment were not recorded, and any short-term medication (i.e., one week course of antibiotics) were not included.

A psychotropic drug was defined as any drug indicated, either officially licenced or through routine clinical practice, for the treatment of psychosis (schizophrenia), depression or bipolar disorder. Anxiolytic agents were not included in this study. The drugs of interest were identified through review of the British National Formulary (BNF) Drug Dictionary¹. The list was expanded to include drugs licenced overseas and drugs no longer listed in the BNF. As the medication data in the UK Biobank are self-reported, it was necessary to identify all potential names (brand names and generic names in foreign languages) of the medications of interest. These alternate names were identified through review of published drug labels, the websites of the European Medicines Agency (EMA)², the Food and Drug Administration (FDA)³, the Mayo Clinic⁴, the independent website www.drugs.com⁵ and the National Library of Medicine⁶.

¹ MedicinesComplete - British National Formulary. <u>https://www.medicinescomplete.com/mc/bnf/current/</u>

² European Medicines Agency. <u>https://www.ema.europa.eu/</u>

³ U S Food and Drug Administration. <u>https://www.fda.gov/</u>

⁴ Mayo Clinic. <u>https://www.mayoclinic.org/</u>

⁵ Drugs.com | Prescription Drug Information, Interactions & Side Effects. <u>https://www.drugs.com/</u>

⁶ National Library of Medicine's LactMed Database. <u>https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm</u>

⁷ Adapted from: CONSORT 2010 Statement, BMJ 2010;340:c332 <u>http://www.consort-statement.org/</u>

Supplementary figure 1. Adapted CONSORT 2010 statement⁷



CONSORT 2010 Flow Diagram



^a Number of participants who withdrew consent after the initial download of all phenotype data and before the analysis was conducted. Participants who withdrew consent prior to initial download of data were already removed; ^b Note that several subjects report taking both antidepressant(s) and antipsychotic(s) and are included in both analyses; ^c See main body of text for detail on why CYP2D6 ultra-rapid metabolisers were not defined in this analysis.

Methodology: Covariates

Diabetes

There were several items in the UK Biobank which could act as a source of information for whether the patient had diabetes or not, namely ICD-10 diagnosis, self-reported diagnosis of diabetes or self-reported use of antidiabetic medications. Though this would be the most reliable item to use for the purpose of our research, the ICD-10 data was incomplete, covering 410,316 participants and recording 3399 (0.82%) cases of diabetes mellitus. Based on self-reported data, the prevalence of diabetes mellitus in the UK Biobank was 5.28%. This is consistent with UK epidemiological studies which report the prevalence of diabetes mellitus at 7%⁷. We thus concluded that the self-reported data was more reliable in this instance. Based on the data available we were unable to differentiate between type 1 and type 2 diabetes.

Anti-diabetic medications

We identified participants taking insulin, metformin, thiazolidinediones, sulfonylureas, meglitinides, alpha-glucosidase inhibitors. There were no participants within our dataset who have been taking glucagon-like peptide-1 or gastric inhibitory peptide as well as gliflozins. We also identified all brand names of anti-diabetic medications and converted these to their generic equivalents and created a dichotomous variable which reflected the use of the antidiabetic medications.

BMI

A high BMI is an independent risk factor for diabetes; hence it was included in our analyses. BMI at baseline was downloaded directly from the UK Biobank.

Enzyme inhibitors

We identified any participants taking drugs that inhibit CYP2D6 and CYP2C19 activity⁸. In the sample, 1,969 participants were taking a CYP2D6 inhibitor drug including: ranitidine, celecoxib, metoclopramide, chlorphenamine, terbinafine, hydroxyzine or promethazine. We also identified 8,340 participants taking drugs that are known CYP2C19 inhibitors including omeprazole, esomeprazole, lansoprazole, pantoprazole, oestrogen, cimetidine, modafinil, topiramate, indomethacin or oxcarbazepine.

⁷ Whicher, C. A., O'Neill, S., & Holt, R. I. G. (2020). Diabetes in the UK: 2019. *Diabetic Medicine*, *37* (2), 242–247. https://doi.org/10.1111/dme.14225

⁸ CYTOCHROME P450 DRUG INTERACTION TABLE - Drug Interactions. (n.d.). Retrieved September 1, 2020, from https://druginteractions.medicine.iu.edu/MainTable.asp

Covariates in antidepressants' model

As expected, in every antidepressants' model, having diabetes, taking antidiabetic medications, raising BMI and increasing age was associated with higher HbA1c (all p <0.001). In all models apart from venlafaxine, South Asian ethnicity was associated with higher HbA1c level (p range <0.001 - 0.050). African ethnicity was associated with higher HbA1c in following models: citalopram, paroxetine, venlafaxine (p range <0.001 – 0.005). Admix Caucasian ethnicity was associated with higher HbA1c levels in fluoxetine models (p = 0.006 and p = 0.027 accordingly) and Other ethnicity in tricyclic and amitriptyline models (p <0.001, p = 0.002). Male sex was associated with higher HbA1c in citalopram and fluoxetine models. Please refer to supplementary tables 10, 11, 14, 16, 17, 18, 21.

Methods: Assigning metabolic phenotype

We extracted regions of interest for each CYP2D6 and CYP2C19, defined as being 1 megabase (Mb) either side of each gene. Start and stop coordinates are provided in supplementary table 1 and were identified using the University of California Santa Cruz Human Genome Browser⁹.

Supplementary table 1. Showing start and stop positions used to extract relevant genetic data from full UKB sample.

GENE (CHROMOSOME, POSITION)	START POSITION FOR DATA EXTRACTION	STOP POSITION FOR DATA EXTRACTION	
CYP2C19 (CHR10: 96447882- 96612671)	95447882	97612671	
CYP2D6 (CHR 22: 42522501- 42526883)	41522501	43526883	

Supplementary table 2. Frequencies of CYP2C19 diplotypes and metabolic phenotypes in 33,149 Biobank participants taking antidepressants or antipsychotics.

Diplotype	Frequency (N)	Percentage (%)
Poor metaboliser		
CYP2C19*1 / CYP2C19*1	10270	30.98
CYP2C19*1 / CYP2C19*13	1080	3.26
CYP2C19*13 / CYP2C19*1	1034	3.12
CYP2C19*13 / CYP2C19*13	104	0.31

Intermediate metaboliser

⁹ Kent W, Sugnet C, Furey T, et al. The Human Genome Browser at UCSC. Genome Res. 2002;12 (6):996-1006.

CYP2C19*1 / CYP2C19*2	2843	8.58				
CYP2C19*2 / CYP2C19*1	2766	8.34				
CYP2C19*17 / CYP2C19*2	1048	3.16				
CYP2C19*2 / CYP2C19*17	969	2.92				
CYP2C19*1 / CYP2C19*3	475	1.43				
CYP2C19*3 / CYP2C19*1	448	1.35				
CYP2C19*13 / CYP2C19*2	333	1				
CYP2C19*2 / CYP2C19*13	289	0.87				
CYP2C19*17 / CYP2C19*3	183	0.55				
CYP2C19*3 / CYP2C19*17	166	0.5				
Normal metaboliser						
CYP2C19*2 / CYP2C19*2	773	2.33				
CYP2C19*3 / CYP2C19*2	152	0.46				
CYP2C19*2 / CYP2C19*3	125	0.38				
Rapid metaboliser						
CYP2C19*1 / CYP2C19*17	3755	11.33				
CYP2C19*17 / CYP2C19*1	3667	11.06				
CYP2C19*13 / CYP2C19*17	382	1.15				
CYP2C19*17 / CYP2C19*13	357	01.08				
Ultra-rapid metaboliser						

'/' distinguishes two homologous chromosomes. ';' connects several different alleles on the same chromosome

Supplementary table 3. Frequencies of CYP2D6 diplotypes and metabolic phenotypes in 33,149 Biobank participants taking antidepressants or antipsychotics.

Diplotype	Frequency (N)	Percentage (%)
Normal metaboliser		

metaboliser

CYP2D6*29 / CYP2D6*29	5716	17.24
CYP2D6*1 / CYP2D6*29	2848	8.59
CYP2D6*29 / CYP2D6*1	2751	8.3
CYP2D6*1 / CYP2D6*1	2049	6.18
CYP2D6*4 / CYP2D6*1	1556	4.69
CYP2D6*1 / CYP2D6*4	1533	4.62
CYP2D6*29 / CYP2D6*41	1157	3.49
CYP2D6*41 / CYP2D6*29	1155	3.48
CYP2D6*41 / CYP2D6*1	853	2.57
CYP2D6*1 / CYP2D6*41	815	2.46
CYP2D6*29 / CYP2D6*9;CYP2D6*29	416	1.25
CYP2D6*9;CYP2D6*29 / CYP2D6*29	408	1.23
CYP2D6*41 / CYP2D6*41	337	1.02
CYP2D6*1 / CYP2D6*9;CYP2D6*29	208	0.63
CYP2D6*9;CYP2D6*29 / CYP2D6*1	186	0.56
CYP2D6*10 / CYP2D6*29	158	0.48
CYP2D6*3A / CYP2D6*1	132	0.4
CYP2D6*29 / CYP2D6*10	129	0.39
CYP2D6*1 / CYP2D6*3A	118	0.36
Intermediate metaboliser		
CYP2D6*4 / CYP2D6*29	2512	7.58
CYP2D6*29 / CYP2D6*4	2331	7.03
CYP2D6*41 / CYP2D6*4	611	1.84
CYP2D6*4 / CYP2D6*41	589	1.78
CYP2D6*29 / CYP2D6*3A	246	0.74
CYP2D6*3A / CYP2D6*29	244	0.74

CYP2D6*10 / CYP2D6*4	222	0.67
CYP2D6*4 / CYP2D6*10	219	0.66
CYP2D6*4 / CYP2D6*9;CYP2D6*29	169	0.51
CYP2D6*9;CYP2D6*29 / CYP2D6*4	140	0.42
Poor metaboliser		
Poor metaboliser CYP2D6*4 / CYP2D6*4	1468	4.43
Poor metaboliser CYP2D6*4 / CYP2D6*4 CYP2D6*3A / CYP2D6*4	1468 103	4.43 0.31

'/' distinguishes two homologous chromosomes. ';' connects several different alleles on the same chromosome

	CYP2D6			СҮР2С19				
	PM	IM	NM	РМ	IM	NM	RM	UM
Models	HbA1c [mm	ol/mol]*, (SD)					
Antipsychotics	36.78	37.60	37.53	-	-	-	-	-
	(7.26)	(8.54)	(8.30)					
Trievelies	27.00	27 70	27.00	27.75	27.0	27.00	28.00	20.42
Tricyclics	37.60	37.79	37.86	37.75	37.6	37.88	38.00	38.13
	(7.79)	(8.38)	(8.21)	(7.80)	(7.73)	(8.30)	(8.81)	(7.88)
Amitriptyline	37.52	37.93	37.85	37.61	37.64	37.92	38.00	38.08
	(7.86)	(8.60)	(8.18)	(7.28)	(7.84)	(8.31)	(8.86)	(8.06)
Fluoxetine	36.50	36.47	36.65	-	-	-	-	-
	(6.90)	(6.50)	(7.50)					
Paroxetine	40.46	37.50	37.38	-	_	_	_	_
i di oxetine	(15.05)	(0.27)	(7.27)					
	(15.05)	(8.27)	(7.27)					
Citalopram	-	-	-	36.89	36.48	36.67	36.51	36.01
				(7.54)	(6.90)	(7.56)	(7.23)	(6.16)
Sertraline	-	-	-	35.30	36.99	37.15	37.13	37.04
				(4.35)	(7.24)	(7.43)	(7.37)	(8.50)

Supplementary table 4. HbA1c levels and CYP phenotypes across individual and groups of medications.

Venlafaxine	39.49	37.13	37.58	-	-	-	-	-
	(12.38)	(8.56)	(8.06)					

* HbA1c levels diagnostic for impaired glucose regulation: normal < 42 mmol/mol, prediabetes 42 - 47 mmol/mol, diabetes ≥48 mmol/mol

		NIM	154	DM	DM		Overall
		(N=12592)	(N=9825)	(N=1128)	(N=8193)	(N=1411)	(N=33149)
Aį	ge (years)						
	Mean (SD)	56.6 (7.79)	56.6 (7.85)	56.2 (8.01)	56.7 (7.72)	56.6 (7.80)	56.6 (7.80)
	Sex						
	Female	8623 (68.5%)	6751 (68.7%)	749 (66.4%)	5547 (67.7%)	962 (68.2%)	22632 (68.3%)
	Male	3969 (31.5%)	3074 (31.3%)	379 (33.6%)	2646 (32.3%)	449 (31.8%)	10517 (31.7%)
Et	hnicity						
	European	11762 (93.4%)	9205 (93.7%)	1062 (94.1%)	7670 (93.6%)	1307 (92.6%)	31006 (93.5%)
	Admix European	342 (2.7%)	223 (2.3%)	27 (2.4%)	198 (2.4%)	46 (3.3%)	836 (2.5%)
	African	127 (1.0%)	110 (1.1%)	10 (0.9%)	95 (1.2%)	16 (1.1%)	358 (1.1%)
	East Asian	25 (0.2%)	13 (0.1%)	1 (0.1%)	12 (0.1%)	0 (0%)	51 (0.2%)
	Other	178 (1.4%)	149 (1.5%)	19 (1.7%)	109 (1.3%)	24 (1.7%)	479 (1.4%)
	South Asian	158 (1.3%)	125 (1.3%)	9 (0.8%)	109 (1.3%)	18 (1.3%)	419 (1.3%)
HI	oA1c (mmol/mol)						
	Mean (SD)	37.2 (7.89)	37.0 (7.44)	37.0 (7.02)	37.2 (7.90)	37.1 (7.84)	37.1 (7.73)
Di	abetes						
	Yes	1117 (8.9%)	827 (8.4%)	105 (9.3%)	762 (9.3%)	125 (8.9%)	2936 (8.9%)
	No	11475 (91.1%)	8998 (91.6%)	1023 (90.7%)	7431 (90.7%)	1286 (91.1%)	30213 (91.1%)
Та	ıking antidiabetic n	nedication					
	Yes	819 (6.5%)	580 (5.9%)	67 (5.9%)	532 (6.5%)	100 (7.1%)	2098 (6.3%)

Supplementary table 5. Characteristics of CYP2C19 metabolic phenotype in our sample

No	11773	9245	1061	7661	1311	31051
	(93.5%)	(94.1%)	(94.1%)	(93.5%)	(92.9%)	(93.7%)
BMI						
Mean (SD)	28.8 (5.67)	28.7 (5.69)	28.6 (5.34)	28.7 (5.66)	28.6 (5.73)	28.7 (5.67)
Taking CYP2C	19 inhibitor					
Yes	3184 (25.3%)	2364 (24.1%)	283 (25.1%)	2068 (25.2%)	360 (25.5%)	8259 (24.9%)
No	9408 (74.7%)	7461 (75.9%)	845 (74.9%)	6125 (74.8%)	1051 (74.5%)	24890 (75.1%)

Supplementary table 6. Characteristics of CYP2D6 metabolic phenotype in our sample

			DM	Overall	
	(N=23585)	(N=7824)	(N=1740)	(N=33149)	
	(14-23303)	(14-7024)	(N=1740)	(11-33143)	
Age (years)					
Mean (SD)	56.6 (7.80)	56.6 (7.82)	56.6 (7.71)	56.6 (7.80)	
Median [Min, Max]	58.0 [40.0, 71.0]	58.0 [40.0, 70.0]	58.0 [40.0, 70.0]	58.0 [40.0, 71.0]	
Sex					
Female	16086 (68.2%)	5355 (68.4%)	1191 (68.4%)	22632 (68.3%)	
Male	7499 (31.8%)	2469 (31.6%)	549 (31.6%)	10517 (31.7%)	
Ethnicity					
Caucasian	22027 (93.4%)	7342 (93.8%)	1637 (94.1%)	31006 (93.5%)	
Admix Caucasian	620 (2.6%)	181 (2.3%)	35 (2.0%)	836 (2.5%)	
African	262 (1.1%)	78 (1.0%)	18 (1.0%)	358 (1.1%)	
East Asian	36 (0.2%)	10 (0.1%)	5 (0.3%)	51 (0.2%)	
Other	346 (1.5%)	108 (1.4%)	25 (1.4%)	479 (1.4%)	
South Asian	294 (1.2%)	105 (1.3%)	20 (1.1%)	419 (1.3%)	
HbA1c (mmol/mol)					
Mean (SD)	37.1 (7.74)	37.0 (7.57)	37.3 (8.34)	37.1 (7.73)	
Diabetes					
Yes	2106 (8.9%)	670 (8.6%)	160 (9.2%)	2936 (8.9%)	
No	21479 (91.1%)	7154 (91.4%)	1580 (90.8%)	30213 (91.1%)	

Taking antidiabetic medication

Yes	1488 (6.3%)	487 (6.2%)	123 (7.1%)	2098 (6.3%)
No	22097 (93.7%)	7337 (93.8%)	1617 (92.9%)	31051 (93.7%)
BMI (kg/m²)				
Mean (SD)	28.7 (5.65)	28.8 (5.67)	28.8 (5.80)	28.7 (5.67)
Taking CYP2D6 inhibitor				
Yes	1401 (5.9%)	440 (5.6%)	102 (5.9%)	1943 (5.9%)
No	22184 (94.1%)	7384 (94.4%)	1638 (94.1%)	31206 (94.1%)

Supplementary table 7. CYP2D6 metabolic phenotypes of people taking antidepressants

	NM	IM	РМ	Overall
	(N=23749)	(N=7816)	(N=1757)	(N=33367)
Antidepressant	23794 (100%)	7816 (100%)	1757 (100%)	33367 (100%)
Tricyclic				
amitriptyline	5840 (24.5%)	1929 (24.7%)	422 (24.0%)	8191 (24.5%)
dosulepin	1158 (4.9%)	349 (4.5%)	64 (3.6%)	1571 (4.7%)
lofepramine	231 (1.0%)	71 (0.9%)	21 (1.2%)	323 (1.0%)
clomipramine	221 (0.9%)	91 (1.2%)	8 (0.5%)	320 (1.0%)
nortriptyline	197 (0.8%)	63 (0.8%)	12 (0.7%)	272 (0.8%)
imipramine	139 (0.6%)	51 (0.7%)	15 (0.9%)	205 (0.6%)
trimipramine	62 (0.3%)	19 (0.2%)	4 (0.2%)	85 (0.3%)
SSRI				
citalopram	5381 (22.6%)	1753 (22.4%)	411 (23.4%)	7545 (22.6%)
fluoxetine	3888 (16.3%)	1282 (16.4%)	299 (17.0%)	5469 (16.4%)
sertraline	1394 (5.9%)	456 (5.8%)	105 (6.0%)	1955 (5.9%)
paroxetine	1367 (5.7%)	457 (5.8%)	106 (6.0%)	1930 (5.8%)
escitalopram	795 (3.3%)	249 (3.2%)	55 (3.1%)	1099 (3.3%)
SNRI				
venlafaxine	1354 (5.7%)	430 (5.5%)	103 (5.9%)	1887 (5.7%)
duloxetine	325 (1.4%)	119 (1.5%)	16 (0.9%)	460 (1.4%)
Tetracyclic				
mirtazapine	869 (3.7%)	316 (4.0%)	74 (4.2%)	1259 (3.8%)

SARI

trazodone	412 (1.7%)	139 (1.8%)	33 (1.9%)	584 (1.8%)
NRI				
reboxetine	38 (0.2%)	10 (0.1%)	6 (0.3%)	54 (0.2%)
OTHER				
other	123 (0.5%)	32 (0.4%)	3 (0.2%)	158 (0.5%)

NM - normal metaboliser, PM - poor metaboliser, IM – intermediate metaboliser, SSRI – Selective Serotonin Reuptake Inhibitor, SNRI – Selective Noradrenaline Reuptake Inhibitor, MOI – Monoamine Oxidase Inhibitor, NRI – Noradrenaline Reuptake Inhibitor, NDRI – Noradrenaline Dopamine Reuptake Inhibitor, SARI – Serotonin Antagonist and Reuptake Inhibitor

Other - doxepin, fluvoxamine, phenelzine, moclobemide, tranylcypromine, bupropion, mianserin, isocarboxazid

Supplementary table 8. CYP2C19 metabolic phenotypes of people taking antidepressants

	NM	IM	PM	RM	UM	Overall
	(N=12689)	(N=9889)	(N=1122)	(N=8241)	(N=1426)	(N=33367)
Antidepressant	12689	9889	1122	8241	1426	33367
	(100%)	(100%)	(100%)	(100%)	(100%)	(100%)
Tricyclic						
amitriptyline	3116	2483	263	1961	368	8191
	(24.6%)	(25.1%)	(23.4%)	(23.8%)	(25.8%)	(24.5%)
dosulepin	603 (4.8%)	439 (4.4%)	60 (5.3%)	388 (4.7%)	81 (5.7%)	1571 (4.7%)
lofepramine	127 (1.0%)	95 (1.0%)	4 (0.4%)	82 (1.0%)	15 (1.1%)	323 (1.0%)
clomipramine	126 (1.0%)	96 (1.0%)	12 (1.1%)	75 (0.9%)	11 (0.8%)	320 (1.0%)
nortriptyline	98 (0.8%)	73 (0.7%)	7 (0.6%)	85 (1.0%)	9 (0.6%)	272 (0.8%)
imipramine	74 (0.6%)	59 (0.6%)	5 (0.4%)	59 (0.7%)	8 (0.6%)	205 (0.6%)
trimipramine	38 (0.3%)	26 (0.3%)	2 (0.2%)	13 (0.2%)	6 (0.4%)	85 (0.3%)
SSRI						
citalopram	2923	2205	232	1882	303	7545
	(23.0%)	(22.3%)	(20.7%)	(22.8%)	(21.2%)	(22.6%)
fluoxetine	2065	1642	195	1338	229	5469
	(16.3%)	(16.6%)	(17.4%)	(16.2%)	(16.1%)	(16.4%)
sertraline	760 (6.0%)	587 (5.9%)	67 (6.0%)	465 (5.6%)	76 (5.3%)	1955 (5.9%)
paroxetine	731 (5.8%)	580 (5.9%)	79 (7.0%)	478 (5.8%)	62 (4.3%)	1930 (5.8%)

	escitalopram	396 (3.1%)	345 (3.5%)	39 (3.5%)	263 (3.2%)	56 (3.9%)	1099 (3.3%)
SN	RI						
	venlafaxine	717 (5.7%)	536 (5.4%)	71 (6.3%)	483 (5.9%)	80 (5.6%)	1887 (5.7%)
	duloxetine	167 (1.3%)	143 (1.4%)	20 (1.8%)	105 (1.3%)	25 (1.8%)	460 (1.4%)
Те	tracyclic						
	mirtazapine	439 (3.5%)	359 (3.6%)	40 (3.6%)	356 (4.3%)	65 (4.6%)	1259 (3.8%)
SA	RI						
	trazodone	220 (1.7%)	169 (1.7%)	18 (1.6%)	155 (1.9%)	22 (1.5%)	584 (1.8%)
NF	1						
	reboxetine	21 (0.2%)	15 (0.2%)	2 (0.2%)	13 (0.2%)	3 (0.2%)	54 (0.2%)
от	HER						
	other	68 (0.5%)	37 (0.4%)	6 (0.5%)	40 (0.5%)	7 (0.5%)	158 (0.5%)

NM - normal metaboliser, PM - poor metaboliser, IM – intermediate metaboliser, RM – rapid metaboliser, UM – ultrarapid metaboliser, SSRI – Selective Serotonin Reuptake Inhibitor, SNRI – Selective Noradrenaline Reuptake Inhibitor, MOI – Monoamine Oxidase Inhibitor, NRI – Noradrenaline Reuptake Inhibitor, NDRI – Noradrenaline Dopamine Reuptake Inhibitor, SARI – Serotonin Antagonist and Reuptake Inhibitor, Other - doxepin, fluvoxamine, phenelzine, moclobemide, tranylcypromine, bupropion, mianserin, isocarboxazid

Supplementary table 9. CYP2D6 metabolic phenotype of individuals taking antipsychotics

	NM	IM	PM	Overall
	(N=2004)	(N=671)	(N=142)	(N=2817)
Antipsychotic	2004 (100%)	671 (100%)	142 (100%)	2817 (100%)
Medication				
prochlorperazine	607 (30.3%)	221 (32.9%)	42 (29.6%)	870 (30.9%)
olanzapine	352 (17.6%)	114 (17.0%)	33 (23.2%)	499 (17.7%)
quetiapine	215 (10.7%)	74 (11.0%)	12 (8.5%)	301 (10.7%)
risperidone	181 (9.0%)	56 (8.3%)	10 (7.0%)	247 (8.8%)
chlorpromazine	105 (5.2%)	40 (6.0%)	6 (4.2%)	151 (5.4%)
flupentixol	107 (5.3%)	36 (5.4%)	5 (3.5%)	148 (5.3%)
trifluoperazine	110 (5.5%)	25 (3.7%)	6 (4.2%)	141 (5.0%)
amisulpride	57 (2.8%)	17 (2.5%)	5 (3.5%)	79 (2.8%)

haloperidol	51 (2.5%)	17 (2.5%)	5 (3.5%)	73 (2.6%)
aripiprazole	43 (2.1%)	16 (2.4%)	4 (2.8%)	63 (2.2%)
sulpiride	41 (2.0%)	14 (2.1%)	4 (2.8%)	59 (2.1%)
other	135 (6.7%)	41 (6.1%)	10 (7.0%)	186 (6.6%)

NM - normal metaboliser, PM - poor metaboliser, IM – intermediate metaboliser. Other - fluphenazine, clozapine, promazine, zuclopenthxol, perphenazine, pipotiazine, periciazine, levomepromazine, benperidol, pimozide, thioridazine, sertindole

Supplementary figure 2. Interaction between diabetes status and metabolic phenotypes among subjects taking, from left to right, (a) tricyclic antidepressants; (b) Amitriptyline; (c) Fluoxetine; (d) Venlafaxine; (e) Citalopram; (f) Sertraline.



Supplementary table 10. Association between CYP2D6 metabolic phenotype and HbA1c within individuals taking paroxetine – additional detail

Paroxetine				
Predictors	Estimates	CI	p	
CYP2D6 IM	0.23	-0.42,0.87	0.489	
CYP2D6 PM	2.43	1.23,3.63	<0.001	

Takes CYP2D6 inhibitor	-0.34	-1.55,0.87	0.577
Sex: Male	0.41	-0.16,0.98	0.158
Age at recruitment	0.15	0.11,0.19	<0.001
Ethnicity: Admix Caucasian	0.14	-1.39,1.68	0.856
Ethnicity: African	6.41	2.96,9.86	<0.001
Ethnicity: East Asian	-0.90	-12.83,11.03	0.882
Ethnicity: Other	0.56	-1.94,3.06	0.661
Ethnicity: South Asian	6.76	3.92,9.59	<0.001
Diabetes	6.85	5.11,8.59	<0.001
ВМІ	0.14	0.09,0.19	<0.001
Antidiabetics	12.89	10.88,14.89	<0.001
Observations	1930		
R ² / R ² adjusted	0.454 / 0.450		

Supplementary table 11. Association between CYP2D6 metabolic phenotype and HbA1c within individuals taking fluoxetine – additional detail

Fluoxetine				
Predictors	Estimates	CI	p	
CYP2D6 IM	0.06	-0.29,0.41	0.728	
CYP2D6 PM	0.04	-0.62,0.69	0.916	
Diabetes: CYP2D6 IM	-3.78	-5.03,-2.53	<0.001	
Diabetes: CYP2D6 PM	-1.81	-4.11,0.49	0.124	
Takes CYP2D6 inhibitor	0.01	-0.62,0.64	0.970	
Sex: Male	0.36	0.04,0.67	0.027	
Age at recruitment	0.15	0.13,0.17	<0.001	
Ethnicity: Admix Caucasian	1.27	0.36,2.17	0.006	

Ethnicity: African	0.80	-0.75,2.34	0.314
Ethnicity: East Asian	1.84	-1.63,5.31	0.299
Ethnicity: Other	0.28	-0.91,1.47	0.640
Ethnicity: South Asian	3.68	2.03,5.34	<0.001
Diabetes	7.22	6.20,8.23	<0.001
BMI	0.16	0.13,0.18	<0.001
Antidiabetics	12.50	11.39,13.62	<0.001
Observations	5469		
R ² / R ² adjusted	0.467 / 0.465		

Supplementary table 12. Association between CYP2D6 metabolic phenotype and HbA1c within individuals taking venlafaxine – additional detail

	Venlafaxine		
Predictors	Estimates	CI	p
CYP2D6 IM	-0.23	-0.89,0.43	0.489
CYP2D6 PM	-0.46	-1.73,0.80	0.495
Diabetes: CYP2D6 IM	3.62	1.27,5.98	0.003
Diabetes: CYP2D6 PM	11.44	8.05,14.84	4.79e-11
Takes CYP2D6 inhibitor	-0.37	-1.50,0.77	0.525
Sex: Male	0.41	-0.14,0.97	0.146
Age at recruitment	0.14	0.11,0.18	<0.001
Ethnicity: Admix Caucasian	0.42	-1.17,2.02	0.602
Ethnicity: African	4.59	1.37,7.80	0.005
Ethnicity: East Asian	-0.96	-12.42,10.51	0.870
Ethnicity: Other	1.97	-0.62,4.56	0.136
Ethnicity: South Asian	2.63	-0.09,5.35	0.058

Diabetes	5.68	4.04,7.33	1.77e-11
BMI	0.15	0.10,0.20	<0.001
Antidiabetics	14.82	12.97,16.67	<0.001
Observations	1885		
R ² / R ² adjusted	0.528 / 0.524		

Model adjusted by age, ethnicity, sex, taking inhibitors of CYP2D6, taking antidiabetics and BMI Normal metabolisers of CYP2D6: 1,352; normal metabolisers of CYP2D6:diabetes = 135

Supplementary table 13. Association between CYP2C19 metabolic phenotype and HbA1c within individuals taking citalopram

		Citalopram	
Predictors	Estimates	CI	ρ
CYP2C19 IM	-0.06	-0.36,0.24	0.701
CYP2C19 PM	0.25	-0.48,0.99	0.500
CYP2C19 RM	-0.07	-0.39,0.24	0.650
CYP2C19 UM	-0.04	-0.68,0.61	0.913
CYP2C19 IM : Diabetes	-2.33	-3.41,-1.25	<0.001
CYP2C19 PM : Diabetes	1.62	-0.97,4.21	0.221
CYP2C19 RM : Diabetes	-0.76	-1.92,0.40	0.198
CYP2C19 UM : Diabetes	-3.78	-6.28,-1.28	0.003
Takes CYP2C19 inhibitor	0.36	0.07,0.65	0.016
Sex: Male	0.29	0.02,0.55	0.032
Age at recruitment	0.13	0.12,0.15	<0.001
Ethnicity: Admix Caucasian	0.02	-0.75,0.80	0.958
Ethnicity: African	1.90	0.58,3.22	0.005
Ethnicity: East Asian	0.45	-2.83,3.73	0.788
Ethnicity: Other	0.81	-0.16,1.78	0.100

Ethnicity: South Asian	3.80	2.78,4.81	<0.001
Diabetes	7.53	6.55,8.51	<0.001
BMI	0.16	0.14,0.19	<0.001
Antidiabetics	12.59	11.65,13.52	<0.001
Observations		7545	
R ² / R ² adjusted		0.470 / 0.468	

Supplementary table 14. Stratified analysis of people taking citalopram

				Cit	alopram			
			Diabetes			No diabet	es	
Predictors	N	Estimates	CI	p	N	Estimates	CI	p
CYP2C19 IM	181	-2.42	-4.99, 0.16	0.066	2024	-2.42	-0.29, 0.18	0.635
CYP2C19 PM	19	1.37	-4.81, 7.54	0.664	213	1.37	-0.31, 0.80	0.392
CYP2C19 RM	140	-1.03	-3.82, 1.76	0.470	1742	-1.03	-0.31, 0.17	0.557
CYP2C19 UM	20	-4.07	-10.09, 1.94	0.184	283	-4.07	-0.52, 0.46	0.894
Observatio	ns		583			6962		
R ² / R ² adjus	sted		0.189 / 0.170			0.127 / 0.1	.25	

Model adjusted by age, ethnicity, sex, taking inhibitors of CYP2D6, taking antidiabetics and BMI Normal metabolisers of CYP2C19: citalopram diabetes = 223, sertraline diabetes = 74

Supplementary table 15. Association between CYP2C19 metabolic phenotype and HbA1c within individuals taking sertraline

	Sertraline				
Predictors	Estimates	CI	p		
CYP2C19 IM	0.13	-0.49,0.76	0.679		

CYP2C19 PM	-0.58	-2.02,0.86	0.429
CYP2C19 RM	-0.17	-0.84,0.50	0.618
CYP2C19 UM	-0.47	-1.82,0.89	0.500
CYP2C19 IM : Diabetes	-0.64	-2.68,1.40	0.539
CYP2C19 PM : Diabetes	-5.84	-11.12,-0.56	0.030
CYP2C19 RM : Diabetes	0.17	-1.96,2.30	0.876
CYP2C19 UM : Diabetes	8.52	3.31,13.73	0.001
Takes CYP2C19 inhibitor	-0.05	-0.62,0.52	0.860
Sex: Male	0.04	-0.49,0.58	0.876
Age at recruitment	0.13	0.10,0.16	<0.001
Ethnicity: Admix Caucasian	-0.37	-1.71,0.97	0.588
Ethnicity: African	2.31	-0.51,5.13	0.108
Ethnicity: East Asian	2.91	-2.51,8.32	0.293
Ethnicity: Other	-0.46	-2.61,1.68	0.671
Ethnicity: South Asian	2.29	0.00,4.57	0.050
Diabetes	5.80	4.01,7.60	<0.001
ВМІ	0.18	0.13,0.22	<0.001
Antidiabetics	11.57	9.84,13.30	<0.001
Observations		1955	
R ² / R ² adjusted		0.438 / 0.433	

Supplementary table 16. Stratified analysis of people taking sertraline

					Sertraline		
			Dial	betes		No diabetes	
Predictors	N	Estimates	CI	p	N	Estimates Cl p	

CYP2C19 IM	54	-2.42	-5.07, 3.85	0.787	533	-2.42	-0.35, 0.59	0.621
CYP2C19 PM	5	1.37	-20.28, 3.49	0.165	62	1.37	-1.66, 0.52	0.306
CYP2C19 RM	47	-1.03	-4.28, 5.10	0.863	418	-1.03	-0.69, 0.33	0.494
CYP2C19 UM	71	-4.07	-3.85, 19.04	0.192	71	-4.07	-1.53, 0.52	0.330
Observations			185			1770		
R ² / R ² adjusted	ł		0.232 / 0.17	4		0.133/0).127	

Model adjusted by age, ethnicity, sex, taking inhibitors of CYP2D6, taking antidiabetics and BMI Normal metabolisers of CYP2C19: citalopram diabetes = 223, sertraline diabetes = 74

Supplementary table 17. Association between CYP2D6 and CYP2C19 metabolic phenotype and HbA1c within Amitriptyline

	Amitriptyline			
Predictors	Estimates	CI	p	
CYP2D6 IM	0.04	-0.28,0.37	0.789	
CYP2D6 PM	0.10	-0.51,0.72	0.740	
CYP2C19 IM	-0.10	-0.43,0.23	0.545	
CYP2C19 PM	0.01	-0.79,0.81	0.978	
CYP2C19 RM	-0.13	-0.49,0.23	0.476	
CYP2C19 UM	0.02	-0.66,0.70	0.951	
Diabetes : CYP2D6 IM	1.03	0.02,2.03	0.046	
Diabetes: CYP2D6 PM	-3.41	-5.44,-1.38	0.001	
CYP2C19 IM : Diabetes	-0.07	-1.12,0.97	0.889	
CYP2C19 PM : Diabetes	-1.67	-4.01,0.67	0.163	
CYP2C19 RM : Diabetes	0.46	-0.61,1.53	0.401	

Observations	8191		
ВМІ	0.16	0.13,0.18	<0.001
Antidiabetics	12.36	11.43,13.29	<0.001
Diabetes	6.68	5.64,7.73	<0.001
Ethnicity: South Asian	2.90	1.81,4.00	<0.001
Ethnicity: Other	1.74	0.66,2.82	0.002
Ethnicity: East Asian	-1.41	-5.83,3.00	0.531
Ethnicity: African	2.57	1.42,3.72	<0.001
Ethnicity: Admix Caucasian	0.07	-0.84,0.98	0.886
Age at recruitment	0.12	0.10,0.14	<0.001
Sex: Male	0.09	-0.20,0.38	0.532
Takes CYP2C19 inhibitor	0.37	0.09,0.65	0.009
Takes CYP2D6 inhibitor	-0.28	-0.78,0.23	0.280
CYP2C19 UM : Diabetes	0.06	-2.06,2.18	0.955

Supplementary table 18. Stratified analysis of people taking amitriptyline

	Amitriptyline								
			Diabetes			No diabet	es		
Predictors	Ν	Estimates	CI	p	Ν	Estimates	CI	p	
CYP2D6 IM	197	1.18	-0.93, 3.30	0.273	1732	0.04	-0.19, 0.28	0.733	
CYP2D6 PM	39	-2.92	-7.23, 1.39	0.184	383	0.10	-0.35, 0.55	0.671	
CYP2C19 IM	248	-0.26	-2.46, 1.95	0.819	2235	-0.09	-0.33, 0.15	0.473	
CYP2C19 PM	31	-1.43	-6.33, 3.48	0.568	232	0.04	-0.54, 0.62	0.902	

235	0.07	-2.19, 2.32	0.952	1726	-0.12	-0.38, 0.14	0.366
38	-0.09	-4.55, 4.37	0.969	330	0.05	-0.45, 0.54	0.851
		874			7317		
ed		0.158 / 0.142			0.100 / 0.09	8	
	235 38	235 0.07 38 -0.09	235 0.07 -2.19, 2.32 38 -0.09 -4.55, 4.37 874 ed 0.158 / 0.142	235 0.07 -2.19, 2.32 0.952 38 -0.09 -4.55, 4.37 0.969 874 ed 0.158 / 0.142	235 0.07 -2.19, 2.32 0.952 1726 38 -0.09 -4.55, 4.37 0.969 330 874 ed 0.158 / 0.142	235 0.07 -2.19, 2.32 0.952 1726 -0.12 38 -0.09 -4.55, 4.37 0.969 330 0.05 874 7317 ed 0.158 / 0.142 0.100 / 0.09	235 0.07 -2.19, 2.32 0.952 1726 -0.12 -0.38, 0.14 38 -0.09 -4.55, 4.37 0.969 330 0.05 -0.45, 0.54 874 7317 ed 0.158 / 0.142 0.100 / 0.098

Supplementary table 19. Association between CYP2D6 and CYP2C19 metabolic phenotype and HbA1c within individuals taking tricyclic antidepressants

	Tricyclic antide	pressants	
Predictors	Estimates	CI	p
CYP2D6 IM	0.04	-0.26,0.34	0.793
CYP2D6 PM	0.13	-0.46,0.72	0.660
CYP2C19 IM	-0.11	-0.42,0.20	0.495
СҮР2С19 РМ	-0.07	-0.83,0.69	0.857
CYP2C19 RM	-0.09	-0.43,0.24	0.594
CYP2C19 UM	0.12	-0.52,0.77	0.709
Diabetes : CYP2D6 IM	0.53	-0.43,1.50	0.279
Diabetes: CYP2D6 PM	-3.85	-5.76,-1.95	<0.001
CYP2C19 IM : Diabetes	-0.49	-1.48,0.51	0.338
CYP2C19 PM : Diabetes	-1.34	-3.50,0.81	0.222
CYP2C19 RM : Diabetes	0.27	-0.75,1.29	0.604
CYP2C19 UM : Diabetes	-0.52	-2.52,1.49	0.613
Takes CYP2D6 inhibitor	-0.26	-0.73,0.21	0.279
Takes CYP2C19 inhibitor	0.39	0.13,0.66	0.004
Sex: Male	0.11	-0.16,0.38	0.428

Observations	9095		
Antidiabetics	12.45	11.58,13.33	<0.001
BMI	0.16	0.13,0.18	<0.001
Diabetes	6.98	5.99,7.97	<0.001
Ethnicity: South Asian	2.55	1.52,3.59	<0.001
Ethnicity: Other	2.19	1.16,3.22	<0.001
Ethnicity: East Asian	0.81	-2.55,4.16	0.638
Ethnicity: African	2.47	1.36,3.57	<0.001
Ethnicity: Admix Caucasian	0.18	-0.67,1.03	0.686
Age at recruitment	0.12	0.11,0.14	<0.001

Supplementary table 20. Stratified analysis of people taking tricyclic antidepressants

		Tricyclics						
			Diabetes			No diabet	es	
Predictors	Ν	Estimates	CI	p	Ν	Estimates	CI	p
CYP2D	1949	0.73	-1.33, 2.78	0.48	208	0.04	-0.18, 0.26	0.740
6 IM				8				
CYP2D	419	-3.30	-7.36, 0.76	0.11	44	0.12	-0.31, 0.54	0.596
6 PM				1				
CYP2C1	2475	-0.61	-2.73, 1.50	0.57	274	-0.09	-0.32, 0.13	0.414
9 IM			-,	0			,	-
	252	-1.26	-5 77 3 25	0 58	37	-0.04	-0 59 0 52	0 899
9 PM	LJL	1.20	5.77, 5.25	4	57	0.04	0.35, 0.32	0.055
CYP2C1	1940	-0.08	-2.24, 2.09	0.94	257	-0.08	-0.33, 0.16	0.501
9 RM				5				
CYP2C1	362	-0.59	-4.84, 3.66	0.78	42	0.15	-0.32, 0.62	0.526
9 UM				6				

Observations	955	8140
R ² / R ² adjusted	0.162 / 0.147	0.101 / 0.099

Model adjusted by age, ethnicity, sex, taking inhibitors of CYP2D6, taking antidiabetics and BMI, Normal metabolisers of CYP2D6: tricyclics diabetes 703, amitriptyline diabetes = 638, Normal metabolisers of CYP2C19: tricyclics diabetes = 345, amitriptyline = 322

Supplementary table 21. Antipsychotics regression model. Association between CYP2D6 metabolic phenotype and HbA1c – additional detail

Antipsychotics				
Predictors	Estimates	СІ	p	
CYP2D6 IM	-0.02	-0.58,0.53	0.930	
CYP2D6 PM	-0.93	-2.01,0.16	0.093	
Takes CYP2D6 inhibitor	0.59	-0.43,1.61	0.260	
Sex: Male	0.40	-0.07,0.88	0.097	
Age at recruitment	0.09	0.06,0.12	<0.001	
Ethnicity: Admix Caucasian	0.78	-0.67,2.23	0.291	
Ethnicity: African	3.81	2.49,5.13	<0.001	
Ethnicity: East Asian	2.31	-1.21,5.83	0.198	
Ethnicity: Other	0.94	-0.70,2.58	0.263	
Ethnicity: South Asian	3.72	2.19,5.26	<0.001	
Diabetes	4.55	3.13,5.97	<0.001	
ВМІ	0.19	0.15,0.23	<0.001	
Antidiabetics	14.18	12.55,15.81	<0.001	
Observations	2699			
R ² / R ² adjusted	0.449 / 0.446			